The systemic inflammatory response to cardiopulmonary bypass.
Although our understanding of the basic pathophysiology of systemic inflammatory response to CPB has significantly advanced in the last 2 decades, these experimentally derived ideas have yet to be fully integrated into clinical practice. Treatment of the systemic inflammatory response to CPB is also confounded by the fact that inhibition of inflammation might disrupt protective physiologic responses or result in immunosuppression. Although it is unlikely that no single therapeutic strategy will ever be sufficient in of itself to totally prevent CPB-associated morbidity, the combination of multiple pharmacologic and mechanical therapeutic strategies, each selectively targeted at different components of the inflammatory response, may eventually result in significantly improved clinical outcomes following cardiac surgery.
Pintar
Tatjana
T
Department of Cardiovascular Anesthesiology, Texas Heart Institute, St. Luke's Episcopal Hospital, 6720 Bertner Avenue, Suite O-520, Houston, TX 77030, USA.
Collard
Charles D
CD
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D002315:Cardiopulmonary Bypass / Q000009:adverse effects*; D006801:Humans; D007249:Inflammation / Q000209:etiology* / Q000473:pathology* / Q000517:prevention & control; D018836:Inflammation Mediators / Q000502:physiology
D000893:Anti-Inflammatory Agents; D018836:Inflammation Mediators